Why Small Manufacturers Are Bringing Sterilization In-House — And Why the Economics Now Work

The assumption that in-house sterilization only makes sense at scale — this was built on the economics of previous generations of sterilization infrastructure. When "in-house" meant a dedicated irradiation vault requiring NRC licensing, radiation shielding rated for Cobalt-60 sources, and a facility management program that rivaled nuclear power plant protocols, the math was unambiguous: only the largest manufacturers could justify it. When it meant an EtO chamber building with ethylene oxide emissions controls, abatement systems, and air monitoring infrastructure required by state environmental agencies, the picture was barely different. Small and mid-size medical device manufacturers outsourced because they had to.

That infrastructure logic no longer governs the decision.

The Architecture of the Old Model

For decades, medical device sterilization was a utility — something manufacturers contracted for, like trucking or warehousing, because building and operating the infrastructure internally was economically and regulatorily impractical below a certain production threshold. Contract sterilizers built a service model around this reality. They aggregated volume from hundreds of device manufacturers, spread fixed infrastructure costs across that base, and delivered sterilized product at per-unit economics that no individual small manufacturer could replicate.

This model was efficient at the industry level. It was also a structural dependency. The manufacturer that relies on a contract sterilizer has introduced a single point of failure into its product release chain — one that operates outside its quality system, on a schedule it does not control, in a facility it does not staff or observe.

For manufacturers of commodity devices produced in large volumes, this dependency was tolerable. For manufacturers of high-value, low-volume devices, combination products, or temperature-sensitive implants, it was always more costly than the per-unit sterilization fee suggested.

What Changed: Regulatory Recognition and Infrastructure Simplification

Two developments have shifted the structural economics — one regulatory, one technological. In January 2024, the FDA formally recognized vaporized hydrogen peroxide as a Category A sterilization method for medical devices, placing it in the same regulatory tier as steam, ethylene oxide, and radiation sterilization. The FDA announcement framed this recognition explicitly as an effort to facilitate broader adoption — acknowledging that expanding the pool of validated sterilization modalities serves both manufacturers and patients.

Category A recognition means VHP sterilization can be submitted to FDA with an abbreviated regulatory pathway. It also means the agency has reviewed the underlying science and the existing body of performance and validation data, and determined that VHP belongs in the same category as sterilization methods with decades of regulatory history. For a device manufacturer evaluating a transition from contract EtO to in-house VHP, this is not a minor administrative detail — it is the foundation of regulatory defensibility.

The technological shift is equally significant. Modern VHP systems are modular, compact, and designed for installation within existing manufacturing footprints. There is no NRC licensing. There is no radiation shielding. There is no emissions infrastructure. Hydrogen peroxide decomposes to water and oxygen — routine decomposition products that require no special abatement. A manufacturer that can accommodate a small controlled room can accommodate a VHP sterilization system.

Contract Sterilization's Rising Cost Base

The economics of contract sterilization are not static — they are under structural upward pressure from two directions simultaneously. On the EtO side, the EPA's enforcement trajectory on commercial sterilizer emissions has been consistent and directional. The EPA's 2024 proposed reconsideration of the Commercial Sterilizer Rule signals continued tightening of permissible emissions limits. The compliance investments required — enhanced emission controls, monitoring systems, operational modifications — represent real capital expenditure for contract sterilizers, and that capital expenditure flows through to customers in the form of higher sterilization fees.

On the gamma side, Cobalt-60 supply is constrained and becoming more so. Reactor capacity limitations and the long production cycles required to produce usable Cobalt-60 create a supply environment where demand can outpace availability. When irradiation capacity is scarce, it is allocated efficiently — meaning smaller customers with lower volume commitments face longer scheduling queues and less pricing leverage. A manufacturer producing batches of 50 to 500 units competes for irradiation time with manufacturers running tens of thousands of units per week. The queue position reflects that asymmetry.

The Custody Problem

Every day a product spends outside the manufacturer's facility is a day of deferred product release — and a day of quality system exposure the manufacturer cannot directly observe or control. The custody problem is not limited to time in the sterilization chamber. It encompasses the entire arc: product preparation for shipment, packaging and labeling for transport, transit to the contract facility, intake and queue time at the facility, the sterilization event, post-sterilization hold, transit back to the manufacturer, receipt inspection, and re-integration into inventory.

For a small manufacturer with a lean team and limited work-in-process inventory, this cycle — often ten to twenty-one business days for gamma sterilization — represents product that cannot be released, revenue that cannot be recognized, and quality records that cannot be closed. It also represents a documentation burden: the manufacturer must trace each lot through a process it did not witness, relying on the contract sterilizer's records to reconstruct what happened.

FDA's Quality Management System Regulation, effective February 2, 2026, does not alter the fundamental accountability structure — the manufacturer retains full responsibility for sterilization process control regardless of where sterilization is performed. What QMSR does is make the documentation standard more explicit and the audit exposure more direct. FDA's QMSR framework and Sterilization Process Controls inspection guidance both make clear that outsourcing sterilization transfers neither responsibility nor accountability. In-house sterilization eliminates the documentation gap between manufacturer and contractor — the quality record is complete and internal.

The Refrigerated Product Problem

For manufacturers of temperature-sensitive products, the contract sterilization calculus is not primarily about scheduling or documentation — it is about product integrity through every transfer in the sterilization cycle. Biologics components, combination devices with pharmaceutical coatings, refrigerated polymer substrates, and devices incorporating temperature-labile materials all require cold chain management that does not pause when product leaves the manufacturer's facility.

With gamma irradiation, maintaining cold chain through the sterilization process means packing product on dry ice for outbound shipment, coordinating with the irradiation facility to maintain cold storage during processing, packing product on dry ice again for return shipment, and re-storing on receipt. Each transfer is a temperature excursion risk. Industry data indicates that approximately 12% of all pharmaceutical shipments experience at least one temperature excursion during transit — a figure representing average conditions, not worst-case scenarios. Domestic dry ice passive cold shipping runs $400 to $1,200 per shipment depending on product volume, transit time, and packaging specification. Each detected excursion triggers a deviation investigation. Each undetected excursion enters the product file without a record.

VHP sterilization at 25–50°C is compatible with temperature-sensitive products in ways that gamma irradiation cannot replicate when cold chain is required. More importantly, in-house VHP means the product never leaves the facility. There is no cold chain break because there is no chain — the product moves from cold storage to the sterilization chamber within the same controlled environment it has occupied since manufacture. The excursion risk does not merely decrease; it is structurally removed from the process.

The True Cost of Outsourcing High-Value, Low-Volume Products

The sterilization fee on the contract sterilizer's invoice is the most visible component of the true cost — and often the smallest. For a manufacturer producing a high-value device at low volumes, the full cost of contract sterilization includes the per-unit sterilization fee, outbound and inbound shipping, cold chain packaging, internal labor to manage the logistics relationship and track lots through the external process, scheduling overhead when cycle availability is constrained, the carrying cost of inventory tied up in transit and queue time, and the cost of any deviation investigations triggered by transit conditions or documentation discrepancies.

For a $500 implant produced in batches of 50 units, that arithmetic looks qualitatively different than it does for a commodity device produced in volumes of 100,000 per month. The contract sterilization model was built for the latter. Manufacturers whose products fall into the former category have historically paid a model-fit penalty — paying for infrastructure designed around volume economics while receiving services calibrated to those same economics.

In-house VHP changes the cost structure: the capital investment is fixed, the operating cost per cycle is predictable, and the elimination of logistics, cold chain, and scheduling overhead removes variable costs that scaled with every batch. The economic inflection point — where in-house sterilization produces a lower total cost per released lot than contract outsourcing — arrives earlier than most manufacturers assume, particularly when the full cost of the outsourced model is calculated rather than the line-item sterilization fee.

Supply Chain Resilience and the 2020 Lesson

**The disruptions of 2020 and the years that followed exposed the degree to which contract sterilization represented a single point of failure** in device manufacturers' product release chains. EtO facility capacity was constrained. Gamma scheduling was disrupted. Manufacturers that had built in-house capability before those constraints materialized controlled their own timelines. Manufacturers without it negotiated for queue position in a seller's market.

The lesson was not subtle: sterilization is not a commodity utility in the way manufacturers had treated it. It is a process-critical step in product release, and its availability is not guaranteed by the existence of a contract. Regulatory guidance and quality system requirements do not pause for supply chain disruptions. Products that cannot be sterilized cannot be released — regardless of where accountability formally resides.

The case for in-house sterilization is partly economic, partly regulatory, and partly operational. The supply chain resilience dimension is not a contingency argument — it is a structural observation about what it means to own the product release process.

SteriFlex and the Modular VHP Platform

SteriFlex is PuroGen's modular VHP sterilization platform — engineered for the production environments of small and mid-size medical device manufacturers. Parametric process control, SAL 10⁻⁶ achievement in cycles as short as 20 minutes, and 21 CFR Part 11-compliant electronic records form the technical foundation. The operational architecture is designed for manufacturers transitioning from contract sterilization: no NRC licensing, no radiation shielding, no emissions controls, no dedicated facility construction required.

The validation pathway follows the FDA Category A framework for VHP — a well-characterized regulatory path that does not require the same magnitude of pre-submission testing as a novel sterilization method. Manufacturers considering this transition who have also evaluated how sterilization integrates into device development earlier in the product lifecycle will find additional context in our earlier analysis of sterilization and the design phase.

The economics now work. The regulatory framework is in place. The infrastructure requirement is within reach of manufacturers who previously had no viable in-house option.

FAQ

**At what production volume does in-house VHP sterilization become economical?**

The threshold depends on product value, batch size, and the true cost of the current outsourced model — including shipping, cold chain, scheduling overhead, and internal labor. Manufacturers of high-value, low-volume devices frequently find that the inflection point is lower than the sterilization fee alone suggests. A full cost-per-released-lot analysis, rather than a per-unit sterilization fee comparison, is the appropriate framework for making this determination.

**How does a manufacturer maintain FDA compliance when transitioning from contract to in-house sterilization?**

The transition requires process validation under the applicable sterilization standard, a 510(k) supplement or PMA supplement if sterilization method or parameters change materially, and updates to the quality system to reflect in-house process ownership. QMSR 2026 makes the documentation requirements for this transition explicit. The FDA Category A pathway for VHP reduces the pre-submission validation burden compared to a novel method submission.

**What does the cold chain break cost a manufacturer per batch when using gamma irradiation for refrigerated products?**

Direct costs include dry ice passive cold shipping at $400–$1,200 per shipment, inbound and outbound, plus temperature monitoring packaging and recertification requirements. Indirect costs include deviation investigation labor when excursions occur, potential batch loss when excursions exceed acceptable thresholds, and the carrying cost of inventory that cannot be released while investigations are open. For products where an excursion-triggered batch loss is a realistic outcome, the expected value calculation changes the in-house economics significantly.

**Does in-house VHP require a dedicated room or special facility infrastructure?**

Modern modular VHP systems are designed to fit within existing manufacturing footprints. There is no requirement for radiation shielding, NRC licensing, or emissions abatement infrastructure. Standard electrical and ventilation requirements apply. The facility and environmental requirements are comparable to other controlled-environment manufacturing processes the manufacturer likely already manages.

**What is the regulatory submission impact of switching from contract EtO to in-house VHP?**

A change in sterilization method from EtO to VHP typically requires a regulatory submission — a 510(k) supplement for cleared devices or a PMA supplement for approved devices — accompanied by sterilization validation data. The FDA Category A recognition for VHP means that the submission pathway is established and the agency has a developed framework for evaluating VHP validation data. The process is manageable and well-characterized, particularly for manufacturers who engage with regulatory strategy early in the transition planning process.